phentermine has been researched along with Chemical Dependence in 15 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity." | 7.80 | Addiction potential of phentermine prescribed during long-term treatment of obesity. ( De Marco, DG; Greenway, FL; Haggard, M; Hendricks, EJ; Hendricks, MJ; Istratiy, Y; Mitchell, CL; Schmidt, SL; Souter, S; Srisurapanont, M, 2014) |
| "Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity." | 3.80 | Addiction potential of phentermine prescribed during long-term treatment of obesity. ( De Marco, DG; Greenway, FL; Haggard, M; Hendricks, EJ; Hendricks, MJ; Istratiy, Y; Mitchell, CL; Schmidt, SL; Souter, S; Srisurapanont, M, 2014) |
| "Phentermine (PT) has been widely used as an anti-obesity drug." | 1.37 | Detection of phentermine in hair samples from drug suspects. ( Choi, H; Chung, H; Chung, KH; In, S; Kim, J; Lee, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, LP | 1 |
| Henningfield, JE | 1 |
| Wang, YG | 1 |
| Lu, Y | 1 |
| Kelsh, D | 1 |
| Vince, B | 1 |
| Sellers, E | 1 |
| Hendricks, EJ | 1 |
| Srisurapanont, M | 1 |
| Schmidt, SL | 1 |
| Haggard, M | 1 |
| Souter, S | 1 |
| Mitchell, CL | 1 |
| De Marco, DG | 1 |
| Hendricks, MJ | 1 |
| Istratiy, Y | 1 |
| Greenway, FL | 1 |
| Lukins, TR | 1 |
| Pett, SI | 1 |
| Brett, J | 1 |
| Rothman, RB | 1 |
| Blough, BE | 1 |
| Baumann, MH | 1 |
| Lee, S | 1 |
| Kim, J | 1 |
| In, S | 1 |
| Choi, H | 1 |
| Chung, H | 1 |
| Chung, KH | 1 |
| Nau, JY | 1 |
| Arfken, CL | 1 |
| Schuster, CR | 1 |
| Johanson, CE | 1 |
| Jasinski, DR | 1 |
| Faries, DE | 1 |
| Moore, RJ | 1 |
| Schuh, LM | 1 |
| Allen, AJ | 1 |
| Rada, PV | 1 |
| Hoebel, BG | 1 |
| Griffiths, RR | 1 |
| Brady, JV | 1 |
| Snell, JD | 1 |
| Valenta, LJ | 1 |
| Cloninger, RT | 1 |
| Papasava, M | 1 |
| Singer, G | 1 |
| Papasava, CL | 1 |
| Sproule, BC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits[NCT04614545] | Phase 4 | 70 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| Treatment With Lorcaserin for Cocaine Use: The TLC Study[NCT03192995] | Phase 2 | 22 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to FDA alert regarding study drug safety) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that took the medication as prescribed (NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of pts completed medication (Number) |
|---|---|
| Virtual Visits | 93.3 |
| Face to Face Visits | 83.3 |
Assessed as percentage of patients who completed all visits (NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of completed patients (Number) |
|---|---|
| Virtual Visits | 82.9 |
| Face to Face Visits | 62.9 |
The primary endpoint is mean change in body weight (%) from baseline (visit 1) to 12 weeks (visit 4) in body weight. (NCT04614545)
Timeframe: 12 weeks
| Intervention | mean change in body weight (%) (Mean) |
|---|---|
| Virtual Visits | -6.61 |
| Face to Face Visits | -7.68 |
(NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of patients on full dose (Number) |
|---|---|
| Virtual Visits | 85.7 |
| Face to Face Visits | 90 |
(NCT04614545)
Timeframe: 12 weeks
| Intervention | Percentage of patients with >5% wt loss (Number) |
|---|---|
| Virtual Visits | 64.7 |
| Face to Face Visits | 70.5 |
To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks
| Intervention | percent adherence (Mean) |
|---|---|
| Experimental | 51.6 |
| Control | 66.2 |
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks
| Intervention | mean percent of visit retention (Mean) | |
|---|---|---|
| Treatment Group | Control Group | |
| Mean Percent of Weekly Follow-up Visits by Treatment and Control Arms | 83 | 81 |
The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Proportion of self-reported weekly cocaine use by Time-Line-Follow-Up (TLFU) at baseline | Proportion of self-reported weekly cocaine use by TLFU at Week 12 | |
| Control | 6 | 6 |
| Experimental | 12 | 7 |
The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Urine positive samples with cocaine use at baseline | Urine positive samples with cocaine use at Week 12 | |
| Control | 0 | 1 |
| Treatment | 8 | 7 |
1 review available for phentermine and Chemical Dependence
| Article | Year |
|---|---|
Dopamine/serotonin releasers as medications for stimulant addictions.
Topics: Animals; Behavior, Addictive; Central Nervous System Stimulants; Cocaine; Dopamine; Dopamine Agents; | 2008 |
3 trials available for phentermine and Chemical Dependence
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
Topics: Adrenergic Uptake Inhibitors; Adult; Carbamates; Cross-Over Studies; Dopamine Uptake Inhibitors; Dos | 2018 |
Abuse liability assessment of atomoxetine in a drug-abusing population.
Topics: Adrenergic Uptake Inhibitors; Adult; Arousal; Atomoxetine Hydrochloride; Central Nervous System Stim | 2008 |
Double-blind trial of anorectic agents.
Topics: Adolescent; Adult; Aged; Amphetamine; Appetite Depressants; Clinical Trials as Topic; Dextroamphetam | 1969 |
11 other studies available for phentermine and Chemical Dependence
| Article | Year |
|---|---|
Topiramate and phentermine: a long story....
Topics: Anti-Obesity Agents; Appetite Depressants; Fructose; Humans; Obesity; Phentermine; Substance-Related | 2013 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Behavior, Addictive; Drug Administration Sched | 2014 |
Is it worth the weight?
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Blood Coagulation Disorders; Cellulitis; Central Nervo | 2013 |
Detection of phentermine in hair samples from drug suspects.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Female; Forensic Toxicology; Gas Chromatograp | 2011 |
[Qnexa: a new anti-obesity threat].
Topics: Anti-Obesity Agents; Central Nervous System Stimulants; Humans; Obesity; Phentermine; Substance-Rela | 2012 |
Postmarketing surveillance of abuse liability of sibutramine.
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Phentermine; Product Surveillance, | 2003 |
Supraadditive effect of d-fenfluramine plus phentermine on extracellular acetylcholine in the nucleus accumbens: possible mechanism for inhibition of excessive feeding and drug abuse.
Topics: Acetylcholine; Animals; Appetite Depressants; Dopamine; Drug Synergism; Feeding Behavior; Fenflurami | 2000 |
Relationship between anorectic and reinforcing properties of appetite suppressant drugs: implications for assessment of abuse liability.
Topics: Animals; Appetite; Appetite Depressants; Chlorphentermine; Cocaine; Dextroamphetamine; Diethylpropio | 1978 |
Letter: Phentermine addiction and thyroxine abuse associated with hypothyroidism.
Topics: Depression; Female; Humans; Hypothyroidism; Middle Aged; Phentermine; Substance-Related Disorders; T | 1975 |
The casual user.
Topics: Dentists; Humans; Phentermine; Professional Impairment; Substance-Related Disorders | 1989 |
Phentermine self-administration in naive free-feeding and food-deprived rats: a dose response study.
Topics: Animals; Food Deprivation; Humans; Male; Phentermine; Rats; Rats, Inbred Strains; Reward; Self Admin | 1985 |